PT - JOURNAL ARTICLE AU - Al-Naamani, Nadine AU - Balte, Pallavi AU - Shashaty, Michael G.S. AU - Sharaf, Asma AU - Terry, James G. AU - Carr, John Jeffrey AU - Allison, Matthew AU - Anderson, Cheryl A.M. AU - Bhatt, Surya P. AU - Long, Michelle T. AU - Christie, Jason D. AU - Oelsner, Elizabeth AU - Anderson, Michaela R TI - Greater pericardial and visceral adiposity increase risk of hospitalization or death from SARS-CoV-2 infection in community dwelling adults: A C4R Study AID - 10.1101/2024.10.02.24314721 DP - 2024 Jan 01 TA - medRxiv PG - 2024.10.02.24314721 4099 - http://medrxiv.org/content/early/2024/10/02/2024.10.02.24314721.short 4100 - http://medrxiv.org/content/early/2024/10/02/2024.10.02.24314721.full AB - Importance Higher body mass index (BMI) increases risk of respiratory failure and death from SARS-CoV-2 infection. BMI is imprecise and fails to account for adipose tissue distribution.Objective To determine whether pericardial adipose tissue (PAT), abdominal visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT), or hepatic adipose deposition on pre-pandemic computed tomography (CT) scans associate with increased risk of hospitalization or death from SARS-CoV-2.Design The Collaborative Cohort of Cohorts for COVID-19 Research (C4R) ascertained SARS-CoV-2 outcomes among participants from 14 US-based cohort studies. This analysis includes participants enrolled in the Jackson Heart, CARDIA, MESA, and Framingham Heart studies.Participants C4R attempted to enroll all cohort participants who were alive on March 1, 2020 and had not withdrawn consent for cohort participation.Exposures Adipose depot size measured on research CT scans performed between 2000 and 2011.Outcome Time from March 1, 2020 to hospitalization or death from SARS-CoV-2 infection ascertained by self- report or active surveillance and confirmed when available, by protocolized record review.Results There were 8412 participants with at least one CT adipose measure, among whom 184 events occurred over a median (interquartile range) of 547 (338-609) days. Participants were 57% female with median (SD) age of 69.1 (10.4) years. In adjusted models, both higher PAT (per doubling in PAT volume, HR 1.62, 95% CI 1.25-2.09) and higher VAT (per 1-standard deviation, HR 1.41, 95% CI 1.20-1.67) were associated with greater hazards of hospitalization or death from SARS-CoV-2. Associations remained after adjustment for BMI, diabetes, cardiovascular disease, and hypertension. SAT was associated with hospitalization or death from SARS-CoV-2 but not after adjustment for BMI, diabetes, cardiovascular disease or hypertension. Hepatic adipose deposition was not associated with hospitalization or death. Associations did not vary by sex, age, race, cohort, smoking status, diabetes, or BMI.Conclusions and Relevance Greater CT-measured pericardial and abdominal visceral adipose tissue were associated with increased hazards of hospitalization or death from SARS-CoV-2 independent of BMI or clinical cardiometabolic comorbidities. Further research should investigate use of CT adipose measures to quantify risk of severe disease from viral infections and to investigate mechanisms linking adiposity to lung injury.Question Is ectopic adipose deposition measured on pre-pandemic CT scan associated with risk of respiratory failure from SARS-CoV-2?Findings In this retrospective cohort study of 8812 participants enrolled in 4 large cohort studies pre- pandemic, greater pericardial and abdominal visceral adipose tissue were associated with increased risk of severe SARS-CoV-2 infection independent of body mass index, diabetes, hypertension, and cardiovascular disease.Meaning Pericardial and abdominal visceral adipose tissue are associated with increased risk of hospitalization or death from SARS-CoV2 independent of existing measures of obesity; use of these measures could improve our risk assessments.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by: NHLBI K23 150280, NHLBI K23 HL 141584 The Collaborative Cohort of Cohorts for COVID-19 Research (C4R) Study is supported by grant OT2HL156812 from the NHLBI Collaborating Network of Networks for Evaluating COVID-19 and Therapeutic Strategies/Researching COVID to Enhance Recovery, with co-funding from the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute on Aging (NIA). The Coronary Artery Risk Development in Young Adults (CARDIA) Study is conducted and supported by the NHLBI in collaboration with the University of Alabama at Birmingham (contracts HHSN268201800005I and HHSN268201800007I), Northwestern University (contract HHSN268201800003I), the University of Minnesota (contract HHSN268201800006I), and the Kaiser Foundation Research Institute (contract HSN268201800004I). The Framingham Heart Study has received support from the NHLBI (grant N01-HC-25195, contract HHSN268201500001I, and grant 75N92019D00031). The Jackson Heart Study is supported by and conducted in collaboration with Jackson State University (contract HHSN268201800013I), Tougaloo College (contract HHSN268201800014I), the Mississippi State Department of Health (contract HHSN268201800015I), the University of Mississippi Medical Center (contracts HHSN268201800010I, HHSN268201800011I, and HHSN268201800012I), the NHLBI, and the National Institute on Minority Health and Health Disparities. The Multi-Ethnic Study of Atherosclerosis (MESA) and the MESA SNP Health Association Resource (SHARe) are conducted and supported by the NHLBI in collaboration with the MESA investigators. Support for MESA is provided by grants and contracts 75N92020D00001, HHSN268201500003I, N01-HC-95159, 75N92020D00005, N01-HC-95160, 75N92020D00002, N01-HC-95161, 75N92020D00003, N01-HC-95162, 75N92020D00006, N01-HC-95163, 75N92020D00004, N01-HC-95164, 75N92020D00007, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169, R01-HL077612, R01-HL093081, R01-HL130506, R01-HL127028, R01-HL127659, R01-HL098433, R01-HL101250, and R01-HL135009 from the NHLBI; grant R01-AG058969 from the NIA; and grants UL1-TR-000040, UL1-TR-001079, and UL1-TR-001420 from the National Center for Advancing Translational Sciences.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Cohorts obtained institutional review board approval from all participating centers: Boston University, Columbia University, University of Alabama Birmingham, Northwestern University, University of Minnesota, Kaiser Foundation Research Institute, Jackson State University, Tougaloo College, University of Mississippi Medical Center, Wake Forest University, Johns Hopkins University, University of Minnesota, Northwestern University, and University of California - Los Angeles. Authors obtained IRB approval from the University of Pennsylvania for completion of the analyses reported in this manuscript.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesRaw deidentified data is available, upon request and with appropriate consortium and cohort permissions, on the C4R Analysis Commons. C4R Analysis Commons, hosted on BioData Catalyst powered by Seven Bridges (https://accounts.sb.biodatacatalyst.nhlbi.nih.gov/). https://c4r-nih.org